Narrative review / 2024
Approved obesity medications added to lifestyle interventions improve long-term weight loss and cardiometabolic risk factors over lifestyle interventions alone.
This narrative review synthesized data on the efficacy and safety of medications approved for long-term obesity management. Compared with lifestyle interventions alone, all approved obesity medications were more effective for long-term weight loss and cardiometabolic improvements. Older medications were associated with mean weight losses of 5-10%, while newer incretin analogues (semaglutide and tirzepatide) were linked to sustained mean reductions of 15-20%. The review notes challenges including cost, availability, weight regain, and loss of lean muscle and bone mineral density.
- Study type
- Narrative review
- Who was studied
- People with BMI ≥30 kg/m2 or BMI ≥27 kg/m2 with excess weight-related conditions
- What was measured
- Efficacy and safety of obesity medications, weight loss, cardiometabolic risk factors
THE PAPER
Obesity medications: A narrative review of current and emerging agents.
Qi QYD, Cox A, McNeil S, Sumithran P. Osteoarthr Cartil Open, 2024.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.